Drug Database
TR

trastuzumab (Saituo / TQB211 / TQ B211)

✓ Approved

Sino Biopharmaceutical Co., Ltd · ERBB2 · 单克隆抗体

什么是 trastuzumab?

trastuzumab 是一种单克隆抗体,由Sino Biopharmaceutical Co., Ltd研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

商品名Saituo, TQB211, TQ B211
公司Sino Biopharmaceutical Co., Ltd
药物类别单克隆抗体, 抗体
分子靶点ERBB2
给药途径Injectable (Others), Intravenous (IV)
状态Approved

作用机制

分子靶点

trastuzumab 作用于 1 个分子靶点:

ERBB2erb-b2 receptor tyrosine kinase 2 (NEU, CD340)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

trastuzumab 针对 3 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Gastric cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Oesophageal carcinomaPreclinical

相关研究文献

PubMedNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026-11-18

Safety and quality of life outcome of trans-anal irrigation for chronic constipation in Parkinson's disease: a pilot study.

Colucci Fabiana F, Ascanelli Simona S, Chimisso Laura L, Antenucci Pietro P et al.

Constipation in Parkinson's Disease (PD) is the main and most disabling non-motor symptom. Laxatives, prebiotics and probiotics are therapeutic options for neurological bowel diseases, and recently, Trans-Anal Irrigation (TAI) has also been considered in poor responders to medical treatment. The primary aim was to evaluate safety and indication of TAI in treating PD constipation. A pilot, prospective, observational, cohort study enrolled PD patients with chronic constipation. At baseline, TAI was proposed. Patients who accepted TAI had a neurological and proctological assessment at baseline (T0), 6-month (T1) and 12-month (T2). Twelve patients accepted TAI. At T1 and T2, no side effects were recorded. TAI patients showed statistically improved proctological assessment (p < 0.001) and unchanged neurological scores except for the PDQ-39 questionnaire (p < 0.001) at T2. TAI is safe for constipation treatment in PD. Improving intestinal transit might ameliorate quality of life, laying the foundation for new therapeutic strategies.

PMID 43045859
阅读全文 →
PubMedFrontiers in oncology2026-11-18

Case Report: Trastuzumab-deruxtecan as 11th line therapy in a metastasized ovarian clear cell carcinoma patient expressing HER2 1.

Wolfrum Angelika A, Ladurner Julia J, Abendstein Burghard B

Ovarian clear cell carcinoma (OCCC) is a rare histologic subtype of epithelial ovarian cancer, accounting for approximately 5%-10% of cases in Western populations. Compared with high-grade serous ovarian cancer, OCCC is characterized by lower sensitivity to conventional cytotoxic chemotherapy and consequently poor outcomes. Given the limited efficacy of standard systemic therapies, there is a considerable unmet need for novel treatment strategies in OCCC. Antibody-drug conjugates (ADCs) have emerged as a promising therapeutic class across several solid tumors. Among these agents, trastuzumab deruxtecan (TDXd) has demonstrated substantial clinical activity in HER2-expressing malignancies and has recently shown efficacy across multiple tumor types in the DESTINY-PanTumor02 trial, but with low evidence in OCCC. Here, we report a patient with heavily pretreated recurrent ovarian clear cell carcinoma who achieved a durable and clinically meaningful response to trastuzumab deruxtecan despite low HER2 expression (IHC 1+).

PMID 43047483
阅读全文 →
PubMedFrontiers in nuclear medicine2026-11-18

Automated cassette-based production, purification, and radiolabeling of [89Zr]Zr-DFO-trastuzumab.

Tesse Giuseppe G, Capasso Giuseppe G, Cazzola Emiliano E, Tolomeo Anna A et al.

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is an aggressive subtype of breast cancer in which accurate, non-invasive assessment of HER2 expression is critical for the stratification of patients and monitoring of treatment. Immuno-positron emission tomography using monoclonal antibodies radiolabeled with long-lived positron emitters, such as [89Zr]zirconium, enables whole-body visualization and quantification of HER2 expression. This study aimed to develop and validate a fully integrated, sequential, and automated cassette-based synthesis process for the production, purification, and radiolabeling of [89Zr]Zr-desferrioxamine (DFO)-trastuzumab for potential clinical application. In this study, [89Zr]zirconium was produced via cyclotron irradiation of sintered [89Y]yttrium solid targets, followed by purification using a hydroxamate-based solid-phase extraction (SPE) system. The resulting [89Zr]Zr(C2O4)2 was used to radiolabel trastuzumab preconjugated with the chelator DFO, and the final radiopharmaceutical was purified via PD-10 size-exclusion chromatography. The automated workflow integrated target dissolution, [89Zr]zirconium capture and elution, buffer adjustment, antibody radiolabeling, PD-10 purification, and sterile filtration within a single disposable cassette installed on an AllinOne synthesis module. The principal process parameters investigated were target dissolution time, acid concentration and washing volumes, [89Zr]zirconium elution conditions, reaction temperature, reaction time, antibody concentration, and starting activity. Preliminary manual radiolabeling experiments were performed at 37 °C to define the radiolabeling conditions, whereas the subsequent automated radiolabeling reaction was performed at 30 °C for 60 min. Radiochemical purity (RCP) and radiochemical yield (RCY) were evaluated via high-performance liquid chromatography (HPLC) and thin-layer chromatography (TLC). All steps were integrated into a single-use cassette installed on a commercial synthesis module to minimize manual handling. Target dissolution and SPE purification yielded [89Zr]Zr(C2O4)2 with an average recovery of approximately 90% and high radionuclidic purity. In preliminary manual experiments, radiolabeling yields of approximately 90% were obtained after 60 min. In contrast, four subsequent automated production runs using starting activities ranging from 37 to 185 MBq showed isolated radiochemical yields ranging from 65% to 78%. The HPLC radiochemical purity was 100% in all automated production runs, while TLC analysis of the final product showed 99%-100% radiochemical purity. Following PD-10 purification, the final product showed 99%-100% radiochemical purity in TLC and a pH of approximately 7. The automated cassette-based workflow demonstrated reproducible radiochemical purity and reduced direct operator handling of the radioactive material, while the lower isolated automated RCY indicated that activity recovery and fluidic transfer efficiency remain areas for further optimization. The developed cassette-based system demonstrated the feasibility of integrating [89Zr]zirconium target dissolution and purification with subsequent radiolabeling and purification of preconjugated DFO-trastuzumab in a single automated sequence. Although the overall automated RCY was lower than the labeling yields obtained in preliminary manual experiments, the consistently high RCP indicates that the main opportunity for further optimization lies in overall activity recovery and fluidic transfer efficiency rather than in the chemical purity of the final product. This process reduces direct operator handling of radioactive material and provides a standardized platform that may be further developed into a Good Manufacturing Practice-compliant production method for [89Zr]-labeled monoclonal antibodies.

PMID 43047657
阅读全文 →
PubMedBioconjugate chemistry2026-11-18

SuFEx-Enabled Tyrosine Specific Bioconjugation of Near-Infrared Fluorophores.

McKay Paula T PT, Nashawati Stefan S, Kodisana Mohan M, Aden Jude E JE et al.

Sulfur (VI) fluoride exchange (SuFEx) chemistry has been widely applied in small-molecule medicinal chemistry, but its translation to near-infrared (NIR) fluorophores and application to antibody labeling remain largely unexplored. Here, we report a general synthetic approach for the preparation of aryl sulfonyl fluoride-functionalized indolenines and their incorporation into heptamethine cyanine (Cy7) fluorophores. The strategy is compatible with a broad range of indolenine substrates bearing diverse electronic and solubilizing substituents, enabling the synthesis of a library of water-soluble, SuFEx-enabled Cy7 fluorophores. Using SAT-NIR-746-SF as a lead probe, we demonstrate that the aryl sulfonyl fluoride handle is stable under physiologically relevant conditions (t1/2 > 18 h at pH 7.4) and enables efficient antibody labeling (degree of labeling up to 6.1) under mild aqueous conditions. The degree of labeling can be systematically controlled by varying reaction pH, incubation time, and reagent stoichiometry. The strategy was successfully applied to therapeutic monoclonal antibodies, including trastuzumab, panitumumab, and cetuximab, and the resulting conjugates were stable under acidic, physiological, and serum conditions. Amino acid selectivity assays and tandem mass spectrometry-based proteomics of labeled trastuzumab confirmed modification exclusively at tyrosine residues, establishing the tyrosine-selective nature of this conjugation platform. SAT-NIR-746-SF-conjugated secondary antibodies provided specific labeling of phospho-histone H3 (H3S10P) in confocal immunofluorescence microscopy. These results establish SuFEx-enabled Cy7 fluorophores as a practical platform for tyrosine-selective antibody bioconjugation and demonstrate their utility in fluorescence imaging applications.

PMID 43046850
阅读全文 →
PubMedFrontiers in chemistry2026-11-18

The advanced biopharmaceutical application of cocrystal.

Inam Muhammad M, Hayat Muhammad M, Osman Abuzar A

Poor aqueous solubility remains a major challenge in drug development, particularly for Biopharmaceutics Classification System (BCS) class II drugs, whose absorption is limited by solubility and dissolution rate. For BCS class IV drugs, which are additionally restricted by permeability, the benefit of solubility enhancement is less predictable. Pharmaceutical cocrystals are a promising and innovative solid-state approach to improve the biopharmaceutical properties of active pharmaceutical ingredients (APIs) without changing their intrinsic chemical structure and pharmacological identity. This review systematically examines the basic design concepts, the wide range of therapeutic applications, and the mechanism of dissolution enhancement and bioavailability improvement of cocrystals. We discuss the integration of cocrystals into synergistic combination therapies, stimuli-responsive smart delivery systems, and advanced nanoscale formulations that enable targeted and controlled drug release. Despite this, there are significant challenges remaining, such as physiological instability in the gastrointestinal tract, manufacturing scalability and reproducibility, rational coformer selection strategies, and regulatory uncertainty exacerbated by sparse pharmacokinetic information and a lack of understanding regarding cocrystal biological interactions at a molecular level. Bringing cocrystal-based formulations to clinical use will take joint, multidisciplinary, and solution-driven efforts across the disciplines of pharmaceutical sciences, materials chemistry, regulatory science, and clinical pharmacology. Finally, pharmaceutical cocrystals represent a promising platform to address solubility restrictions, with growing evidence, predominantly preclinical, of improved therapeutic performance for poorly soluble drugs.

PMID 43048188
阅读全文 →
PubMedGlobal advances in integrative medicine and health2026-11-18

Getting Feasibility Right: Practical Recommendations for Designing and Evaluating Feasibility Studies in Complementary and Integrative Health Research.

Baumgartner Jennifer N JN, Yu Qilu Q, Ratliff Whitney A WA, Jean-Francois Beda B et al.

Feasibility studies represent an important stage in the research pipeline, ensuring that essential building blocks are in place before conducting subsequent definitive clinical trials. While the principles of rigorous feasibility trial design apply across scientific fields, their application to mind and body interventions merits discussion. Mind and body interventions such as meditation, yoga, and tai chi, are complex, behaviorally driven, and require high delivery fidelity. Aligned with the NCCIH Research Framework, feasibility research functions as an iterative process of intervention refinement and optimization to guide translation across the research pipeline. The goal of feasibility work is not to test hypotheses about the effects of an intervention, but rather to inform the planning of a future large-scale trial by assessing key a priori benchmarks of feasibility/acceptability. This article focuses on the utility of feasibility studies in complementary and integrative health research and offers practical recommendations on design and evaluation practices. Our aim is to provide investigators with a detailed roadmap on the "dos and don'ts" of conducting feasibility studies that improves the rigor, reproducibility, and impact of complementary and integrative health research.

PMID 43048482
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多trastuzumab